Literature DB >> 31197822

Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy.

J Erlandsson1,2, D Pettersson1,3, B Glimelius4, T Holm1,2, A Martling1,2.   

Abstract

BACKGROUND: The optimal timing of surgery for rectal cancer after radiotherapy (RT) is disputed. The Stockholm III trial concluded that it was oncologically safe to delay surgery for 4-8 weeks after short-course RT (SRT), with fewer postoperative complications compared with SRT with surgery within a week. Other studies have indicated that an even shorter interval between RT and surgery (0-3 days) might be beneficial. The aim of this study was to identify the optimal interval to surgery after RT.
METHODS: Patients were analysed as treated, in terms of overall treatment time (OTT), the interval from the start of RT until the day of surgery. Patients receiving SRT (5 × 5 Gy) were categorized according to OTT: 7 days (group A), 8-13 days (group B), 5-7 weeks (group C) and 8-13 weeks (group D). Patients receiving long-course RT (25 × 2 Gy) were grouped into those with an OTT of 9-11 weeks (group E) or 12-14 weeks (group F). Outcomes assessed were postoperative complications and early mortality.
RESULTS: A total of 810 patients were analysed (group A, 100; group B, 247; group C, 192; group D, 160; group E, 52; group F, 59). Baseline patient characteristics were similar. There were significantly more overall complications in group B than in groups C and D. Adjusted odds ratios, with B as the reference group, were: 0·72 (95 per cent c.i. 0·40 to 1·32; P = 0·289), 0·50 (0·30 to 0·84; P = 0·009) and 0·39 (0·23 to 0·65; P < 0·001) for groups A, C and D respectively. Early mortality was similar in all groups. There were no significant differences between long-course RT groups.
CONCLUSION: These results suggest that surgery should optimally be delayed for 4-12 weeks (OTT 5-13 weeks) after SRT.
© 2019 BJS Society Ltd. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 31197822     DOI: 10.1002/bjs.11200

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial.

Authors:  Alessandro Passardi; Ilario Giovanni Rapposelli; Emanuela Scarpi; Elisa Neri; Elisabetta Parisi; Giulia Ghigi; Giorgio Ercolani; Andrea Avanzolini; Davide Cavaliere; Britt Rudnas; Martina Valgiusti; Domenico Barone; Fabio Ferroni; Giovanni Luca Frassineti; Antonino Romeo
Journal:  Ther Adv Med Oncol       Date:  2020-12-08       Impact factor: 8.168

2.  Clinical Effect of Radiotherapy Combined with Capecitabine after Neoadjuvant Therapy for Rectal Cancer.

Authors:  Qibo Zhang; Haibin Teng
Journal:  J Oncol       Date:  2021-06-05       Impact factor: 4.375

3.  Preoperative radiotherapy for locally advanced rectal cancer during and after the COVID-19 pandemic.

Authors:  R Mirnezami; J Knowles; A Kar; R Glynne-Jones
Journal:  Br J Surg       Date:  2020-05-28       Impact factor: 6.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.